Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain tractionUptake of Biogen's breakthrough Alzheimer's drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter.[Collection]

Uptake of Biogen's breakthrough Alzheimer's drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter.https://www.cnbc.com/2024/08/01/biogen-biib-earnings-q2-2024.html